Identifying vulnerable cell types in a genetic form of frontotemporal dementia
Characterizing Vulnerable Cell Types in C9orf72-FTD
This study is looking into how certain brain cells are affected by frontotemporal dementia, aiming to understand what makes them vulnerable, so we can learn more about the disease and help those who have it.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11032030 on NIH RePORTER |
What this research studies
This research investigates the genetic causes of frontotemporal dementia (C9-FTD), focusing on how certain brain cells, particularly in the medial orbitofrontal cortex, are affected by the disease. The study aims to understand the role of specific types of neurons and microglia in the progression of C9-FTD by using advanced transcriptomic techniques to analyze their molecular profiles and interactions. By identifying these vulnerable cell types, the research seeks to uncover mechanisms that contribute to the degeneration seen in patients with this condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with genetic mutations associated with frontotemporal dementia, particularly those with C9orf72 expansions.
Not a fit: Patients with other forms of dementia not related to C9orf72 mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new insights into the mechanisms of frontotemporal dementia, potentially paving the way for targeted therapies.
How similar studies have performed: Previous research has shown promise in understanding neurodegenerative diseases through similar approaches, but this specific investigation into C9-FTD is relatively novel.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Dai, David — University of Pennsylvania
- Study coordinator: Dai, David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.